Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine and Peginterferon Alpha-2a in HBeAg-positive CHB
NCT00412750Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Feb 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (3 arms), sponsored by Novartis. Primary endpoints: Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Peginterferon Alpha-2a Monotherapy at 52 weeks and Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at 24 weeks. Started Dec 2006; status: terminated.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00412750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412750.